Cancer Research

Published by: American Association for Cancer Research  

People

  1. Jhaveri
    Jhaveri
  2. Chandarlapaty
    Chandarlapaty
  3. Modi
    Modi
  4. Razavi
    Razavi
  5. Ladewig
    Ladewig
  6. Hudis
    Hudis
  7. Solit
    Solit
  8. Chiosis
    Chiosis
  9. Dang
    Dang
  10. Drago
    Drago

Groups

  1. Breast Medicine Service (33)
  2. Department of Medicine (33)
  3. Solid Tumor Oncology Division (33)
  4. GSK Faculty (10)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (8)
  6. Sloan Kettering Institute Postdocs (8)
  7. Human Oncology and Pathogenesis Program (7)
  8. Radiology, Department of (6)
  9. Survivorship Research (6)
  10. Epidemiology and Biostatistics (5)
Search Within
  1. "Komal Jhaveri"
Formats
  1. Meeting Abstract (31)
  2. Journal Article (2)
Groups
  1. Breast Medicine Service (33)
  2. Department of Medicine (33)
  3. Solid Tumor Oncology Division (33)
  4. GSK Faculty (10)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (8)
  6. Sloan Kettering Institute Postdocs (8)

More Groups

People
  1. Komal Jhaveri (33)
  2. Sarat Chandarlapaty (6)
  3. Shanu Modi (6)
  4. Maurizio Scaltriti (5)
  5. Pedram Razavi (5)
  6. Erik Ladewig (4)

More People

Years
  1. 2022 (1)
  2. 2021 (10)
  3. 2020 (11)
  4. 2019 (5)
  5. 2018 (2)
  6. 2017 (2)

More Years

Publishers
  1. American Association for Cancer Research (33)

Results (33)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The oncogenic PI3K-induced transcriptomic landscape reveals key functions in splicing and gene expression regulation
    Journal Article

    Ladewig, E.; Michelini, F.; Jhaveri, K.; Castel, P.; Carmona, J.; Fairchild, L.; Zuniga, A. G.; Arruabarrena-Aristorena, A.; Cocco, E.; Blawski, R.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Monitoring circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) genomic alterations in ER positive (POS)/HER2 negative (NEG) advanced breast cancer during endocrine therapy: Correlative study of AZD9496 oral SERD phase I trial
    Meeting Abstract

    Cani, A. K.; Dolce, E. M.; Darga, E. P.; Hu, K.; Brown, M.; Liu, C. J.; Pierce, J.; Bradbury, K.; Aung, K.; Schiavon, G.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Genomic alterations in PIK3CA-mutated breast cancer result in mTORC1 activation and limit the sensitivity to PI3Kα inhibitors
    Journal Article

    Cai, Y.; Xu, G.; Wu, F.; Michelini, F.; Chan, C.; Qu, X.; Selenica, P.; Ladewig, E.; Castel, P.; Cheng, Y.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2-LA/MBC)
    Meeting Abstract

    Turner, N.; Jhaveri, K.; Kalinsky, K.; Loibl, S.; Loi, S.; Im, S. A.; Saura, C.; Schmid, P.; Schutzman, J. L.; Stout, T. J.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Targeted safety events from a phase I/Ib study evaluating GDC-0077 alone and in combination with endocrine therapy (ET) ± palbociclib (palbo) in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)
    Meeting Abstract

    Olivera, M.; Jhaveri, K.; Juric, D.; Bedard, P. L.; Cervantes, A.; Gambardella, V.; Hamilton, E.; Italiano, A.; Kalinsky, K.; Krop, I. E.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • A phase Ib trial of fulvestrant + CDK4/6 inhibitor (CDK4/6i) palbociclib + pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib in FGFR-amplified/ ER+/ HER2-negative metastatic breast cancer (MBC)
    Meeting Abstract

    Mayer, I. A.; Haley, B. B.; Abramson, V. G.; Brufsky, A.; Rexer, B.; Stringer-Reasor, E.; Jhaveri, K. L.; Sanders, M.; Ericsson-Gonzalez, P. I.; Ye, F.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Preliminary correlative analysis of clinical outcomes with PIK3CA mutation (mut) status from a phase I/Ib study of GDC-0077 in patients (pts) with hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)
    Meeting Abstract

    Jhaveri, K.; Juric, D.; Varga, A.; Turner, N.; Schmid, P.; Saura, C.; Oliveira, M.; Krop, I. E.; Kalinsky, K.; Italiano, A.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with other anticancer agents in patients with HER2-low metastatic breast cancer: A phase 1b, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast08)
    Meeting Abstract

    Jhaveri, K.; Hamilton, E.; Loi, S.; Schmid, P.; Darilay, A.; Gao, C.; Patel, G.; Wrona, M.; Andre, F.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Latest findings from the breast cancer cohort in SUMMIT - A phase 2 'basket' trial of neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer
    Meeting Abstract

    Jhaveri, K.; Saura, C.; Guerrero-Zotano, A.; Spanggaard, I.; Bidard, F. C.; Goldman, J. W.; Garcia-Sáenz, J. A.; Cervantes, A.; Boni, V.; Crown, J.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • A phase I/Ib study evaluating GDC-0077 + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)
    Meeting Abstract

    Bedard, P. L.; Jhaveri, K.; Cervantes, A.; Gambardella, V.; Hamilton, E.; Italiano, A.; Kalinsky, K.; Krop, I. E.; Oliveira, M.; Saura, C.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save

    • Cancer Research – authorized name for:

    Name ISSN / ISBN Publisher
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer Research 15387445 American Association for Cancer Research
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer Research 00085472 American Association for Cancer Research
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer Research 00085472 American Association Tor Cancer Research
    Cancer Research 00085472 American Association for Cancer Research
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer Research 0008-5472 Unknown
    Cancer research 15387445 The Authors the American Association for Cancer Research
    Cancer Research 00085472 American Association for Cancer Research
    Cancer Research 15387445 American Association for Cancer Research
    Cancer research 15387445 American Association for Cancer Research
    Cancer Research 00085472 Unknown
    Cancer Research 00085472 American Association for Cancer Research
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer research 15387445 Unknown
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer Research 00085472 American Association for Cancer
    Cancer Research 00085472 The Authors
    Cancer Research 00085472 The Authors the American Association for Cancer Research